Australian and Indian approval for teriparatide products

Biosimilars/News | Posted 02/04/2021 post-comment0 Post your comment

Australia’s drug regulatory agency, the Therapeutic Goods Administration (TGA), has approved a teriparatide biosimilar and the Drug Controller General of India (DCGI) has approved a teriparatide ‘similar biologic’.

Teriparatide Forteo V21D02

Teriparatide is a recombinant form of parathyroid hormone (PTH). Teriparatide is identical to a portion of human PTH and intermittent use activates osteoblasts more than osteoclasts, which leads to an overall increase in bone. This makes it an effective anabolic, i.e. bone growing, agent. It is therefore used for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women.

The teriparatide biosimilar, Terrosa, which is produced by Hungary-based Gedeon Richter, was approved by Australia’s TGA on 24 November 2020 for the treatment of osteoporosis. The TGA has approved Terrosa for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures. It is also approved for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.

The approval by the TGA marks the first teriparatide biosimilar to be approved for use in Australia. Gedeon Richter also gained approval for Terrosa in Europe in January 2017 [1] and in South Korea in November 2019 [2]. And the company has in-licensed the product to Mochida for the Japanese market, who launched the biosimilar in November 2019 [3].

Enzene Biosciences (Enzene) announced on 4 February 2021 that it had received approval for its teriparatide ‘similar biologic’ from India’s DCGI. Enzyne says that the clinical trial conducted for the teriparatide similar biologic is one of the most comprehensive trials for teriparatide in India and includes pharmacokinetics, immunogenicity and efficacy. The approved product will be launched ‘a fully compliant pen device’ and will be marketed via Alkem Laboratories and Enzyne is also exploring other potential partnering opportunities.

Related articles
Biosimilars of teriparatide

Australian approved biosimilars

Similar Biologics approved in India


To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.



Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 2]. Available from: 
2. GaBI Online - Generics and Biosimilars Initiative. Teriparatide biosimilar Terossa approved in South Korea []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 2]. Available from: 
3. GaBI Online - Generics and Biosimilars Initiative. Bevacizumab and teriparatide biosimilars launched in Japan []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Apr 2]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: Enzyne Bioscience, TGA

comment icon Comments (0)
Post your comment
Related content
EC approval of first ustekinumab biosimilar Uzpruvo
Biosimilars/News Posted 16/01/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010